School of Medicine
Showing 1-10 of 11 Results
-
Amirsaman Ashtari
Postdoctoral Scholar, Radiation Biology
BioI am a postdoctoral researcher at Stanford University, jointly supervised by Ash Alizadeh MD/PhD and Mohammad Shahrokh Esfahani PhD. I developed several AI solutions for the Computer Vision and Computer Graphic domains during my PhD studies at KAIST and ETH Zurich. My PhD research outcome was recognized by winning the Young Researcher Award, and I was eager to apply all those AI techniques to biological data for cancer therapy. In the Alizadeh and Esfahani labs, I will develop AI solutions and computational tools to better understand the tumor microenvironment. Outside of my research, I enjoy loving my family, playing the piano, and listening to music.
-
Lu Ji
Postdoctoral Scholar, Radiation Biology
BioDriven by the enthusiasm and curiosity about life science and human disease, I have been working on cancer research for more than 5 years. I focus on developing novel therapeutic targets from tumor microenvironment and uncovering mechanisms of tumor progression, especially with expertise in gastrointestinal tumor biology and tumor microenvironment analysis. Now I'm digging into a field about finding a way to empower immunotherapy by appropriately utilizing radiation therapy.
-
Jinglong Wang
Postdoctoral Scholar, Radiation Biology
BioDr. Wang was trained at the Jacques Monod Institute and École Normale Supérieure in Paris, France under the mentorship of Dr. Terence Strick. and obtained his Ph.D. degree from the University of Paris in 2019. He dissected the molecular machinery of human and bacterial NHEJ, and interrogated the mechanism of SpCas9 tolerance to non-specific substrate using single-molecule nanomanipulation tools.
Jinglong’s research in the Frock Lab focuses on DSB-related chromosome topological changes and genomic interactions. -
Mengxiong Wang
Postdoctoral Scholar, Radiation Biology
Current Research and Scholarly Interests1. To investigate the role of p53 in regulating the regression of lung adenocarcinoma and tumor microenvironment.
2. To determine synthetic lethal partner for p53 mutations in the context of lung adenocarcinoma.
